PRISMASOL BGK 4/0 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRISMASOL BGK 4/0 IN PLASTIC CONTAINER (PRISMASOL BGK 4/0 IN PLASTIC CONTAINER).
Hemodialysis solution components correct electrolyte imbalances and acid-base disturbances via diffusion and ultrafiltration across a semipermeable membrane.
| Metabolism | Not metabolized; components are excreted or redistributed during dialysis. |
| Excretion | PRISMASOL BGK 4/0 is a replacement solution for continuous renal replacement therapy (CRRT); its components (electrolytes, buffer) are primarily eliminated via the CRRT circuit (ultrafiltration/dialysis). Renal excretion negligible in anuric patients; biliary/fecal elimination not clinically relevant. |
| Half-life | Not applicable as a replacement solution; components follow endogenous kinetics. For bicarbonate buffer, half-life is minutes due to rapid equilibration; for electrolytes, half-life depends on CRRT clearance. |
| Protein binding | <10% for all components (sodium, potassium, magnesium, chloride, bicarbonate/gluconate); no significant protein binding. |
| Volume of Distribution | Total body water (~0.6 L/kg) for electrolytes; distributes throughout extracellular fluid (0.2 L/kg) for bicarbonate. |
| Bioavailability | 100% intravenously; not administered via other routes. |
| Onset of Action | Immediate upon infusion; correction of electrolyte and acid-base disturbances begins within minutes of starting CRRT. |
| Duration of Action | Duration equals CRRT session length; continuous replacement maintains homeostasis until therapy discontinued. |
Intravenous continuous renal replacement therapy (CRRT) using Prismasol BGK 4/0. Typical flow rate: dialysate and replacement fluid at 2000-3000 mL/h, adjusted to achieve desired solute clearance and fluid balance. Dose individualized based on patient size, metabolic rate, and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required; product is specifically designed for use in patients with acute kidney injury requiring CRRT. Dose (flow rate) adjusted based on residual renal function and treatment goals. In patients with preserved renal function not requiring dialysis, use not indicated. |
| Liver impairment | No specific guidance; use with caution in hepatic impairment. Monitor electrolytes and acid-base status. Dose adjustment may be needed if severe hepatic failure impacts metabolic parameters. |
| Pediatric use | Intravenous CRRT: dialysate and replacement fluid flow rates typically 2000-3000 mL/h/1.73 m², adjusted for body surface area. Exact rate determined by nephrologist based on pediatric patient’s size and clinical needs. |
| Geriatric use | Elderly patients: use standard CRRT dosing, with careful monitoring for fluid overload and electrolyte imbalances due to decreased renal reserve. Dose adjustments of flow rate may be necessary based on clinical status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRISMASOL BGK 4/0 IN PLASTIC CONTAINER (PRISMASOL BGK 4/0 IN PLASTIC CONTAINER).
| Breastfeeding | PRISMASOL BGK 4/0 IN PLASTIC CONTAINER is a physiological solution; components are already present in breast milk. No M/P ratio available. Use during breastfeeding is considered safe as it does not contain drugs that would transfer significantly. Maternal electrolyte and fluid balance should be maintained to ensure adequate milk production. |
| Teratogenic Risk | PRISMASOL BGK 4/0 IN PLASTIC CONTAINER is a sterile, nonpyrogenic solution for continuous renal replacement therapy (CRRT). It contains electrolytes and glucose but no drugs. As a physiological solution, it is not associated with teratogenic risk. However, the underlying condition requiring CRRT (e.g., severe acute kidney injury, electrolyte imbalances) poses significant maternal and fetal risks. In pregnancy, CRRT may be necessary for life-threatening conditions; the potential benefits outweigh theoretical risks. No specific teratogenic effects are expected from the solution itself. First trimester: No known fetal harm. Second and third trimesters: No known harm, but maternal acid-base and electrolyte disturbances requiring CRRT can adversely affect fetal outcomes. |
■ FDA Black Box Warning
None
| Serious Effects |
["Severe hypokalemia","Metabolic alkalosis","Hypocalcemia","Hyperphosphatemia with calcium-containing solutions"]
| Precautions | ["Monitor serum electrolytes, acid-base status, and fluid balance closely","Risk of hyperkalemia if potassium-containing solutions are used inappropriately","Risk of aluminum toxicity in patients with renal failure","Use with caution in patients with severe respiratory alkalosis"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, fluid balance, serum electrolytes, acid-base status, and renal function continuously during CRRT. Fetal heart rate monitoring and uterine activity monitoring are recommended if gestational age permits. Assess for signs of fluid overload or dehydration, and electrolyte disturbances that could affect fetal well-being. Regular assessment of maternal hemodynamics and adjustments to CRRT prescription as needed. |
| Fertility Effects | No known direct effects on fertility. PRISMASOL BGK 4/0 IN PLASTIC CONTAINER is a replacement solution and does not contain hormones or reproductive toxins. However, the underlying condition requiring CRRT may impact fertility due to associated systemic illness. |